Medical/Pharmaceuticals

STARMED Unveils New Brand Identity to Drive Global Multi-Modality Strategy

SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ -- STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its seventeenth year of operation, the company is formally transitioning from a Radiofrequency Ablation (RFA) specialist into ...

2026-01-08 10:41 3619

Sky Labs Secures CE-MDR for 'CART PLATFORM,' Accelerating Its Global Market Entry

- 'CART,' the blood pressure ring, recognized in Europe for its advanced vital sign monitoring technology - Targeting the global healthcare market beyond Europe through CE-MDR certification SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ -- Sky Labs (CEO Jack Byunghwan Lee) announced on the 8th th...

2026-01-08 09:15 3139

'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week

PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San Francisco Marriott Marquis, with both in-person and v...

2026-01-06 21:30 3734

Healthcare Holding Schweiz Acquires Stake in Medddbase International

Healthcare Holding Schweiz AG, a leading service provider and distributor of medical technology inSwitzerland, expands its portfolio through the acquisition of a majority stake in Medddbase International AG, which includes Medddbase Schweiz AG and Medddbase Deutschland GmbH. Healthcare Holding Sc...

2026-01-06 19:19 4834

Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report

Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT

2026-01-06 16:21 3779

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program.  Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP service...

2026-01-06 12:03 5669

Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fina...

2026-01-06 07:58 4249

Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted ant...

2026-01-05 20:00 4084

Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China

Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the"Group"), a global wellness group off...

2026-01-05 17:36 2827

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination wi...

2026-01-05 17:29 4433

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application...

2026-01-05 12:07 4043

C&R Research, the 'K-Clinical Hub', Strengthens Partnerships in Indonesia

Accelerating Indonesia Collaboration through Global Clinical Capabilities SEOUL, South Korea, Jan. 5, 2026 /PRNewswire/ -- C&R Research, founded in 1997 as Korea's first full-service Contract Research Organization (CRO), has played a pivotal role in advancing the Korean clinical trial industry an...

2026-01-05 10:00 5622

Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026. -ASC30 demonstrated placebo-...

2026-01-05 08:10 3639

Babies Bliss Establishes a New Standard for Fertility Wellness in Singapore with a Whole-Person, Cycle-Aware Model

Singapore-based Fertility Wellness House positions complementary care as long-term support alongside IVF and assisted fertility treatments SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Babies Bliss, a leading fertility wellness house inSingapore, is redefining how fertility journeys are supported thro...

2026-01-05 07:00 3562

Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula

BANGKOK, Dec. 31, 2025 /PRNewswire/ -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, ...

2025-12-31 15:46 7998

KLMBio Accelerates Global Expansion in Bone Graft Market with Human Tissue-Based Medical Devices

SEOUL, South Korea, Dec. 31, 2025 /PRNewswire/ -- KLMBio, a manufacturer and exporter of human tissue-based medical devices, is accelerating its global business expansion by strengthening its high-value tissue-based product portfolio to target the rapidly growing global bone graft market. The gl...

2025-12-31 12:44 3728

Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange

SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on theHong Kong stock m...

2025-12-31 08:55 6090

HKSH Medical Group and Southern University of Science and Technology Collaborate for Medical and Medical Physics Training, Enhancing Medical Education and Research Innovation

HONG KONG, Dec. 29, 2025 /PRNewswire/ -- HKSH Medical Group ("HKSH") and Southern University of Science and Technology ("SUSTech") officially signed a Memorandum of Understanding ("MOU") on15 December 2025, a significant initiative to deepen collaboration betweenHong Kong and the Chinese Mainland...

2025-12-29 16:12 3692

Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE

SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immu...

2025-12-29 13:52 3534

Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore

SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic,Assure Family Clinic Woodlands. This expansion marks the next phase in the Group's mission to make quality and comprehensive healthca...

2025-12-29 10:00 1884
1234567 ... 396

Week's Top Stories